Brief: Oasmia Pharmaceutical Q2 Operating Loss Narrows To TSEK 56,165

Vivesto AB

19/08/2021 07:13

Aug 19 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * INTERIM REPORT FOR THE PERIOD JANUARY 1, 2021 – JUNE 30,
2021
    * Q2 CONSOLIDATED NET SALES AMOUNTED TO TSEK 4,596 (254)
    * Q2 OPERATING PROFIT/LOSS WAS TSEK -56,165 (-78,296)
    * Q2 NET PROFIT/LOSS AFTER TAX AMOUNTED TO TSEK -57,677
(-80,090)

Source text for Eikon:  ID:nMFN1FM4Cg 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))